尔康制药：关于控股股东减持计划期限届满未减持股份的公告

Core Viewpoint - The announcement from Erkang Pharmaceutical indicates that the controlling shareholder, Mr. Shuai Fangwen, has not reduced his shareholding during the designated reduction period, maintaining a significant ownership stake of 853,574,906 shares, which represents 41.38% of the total share capital [1]. Group 1 - The reduction plan period for the controlling shareholder is set to expire on January 28, 2026 [1]. - Mr. Shuai Fangwen's current shareholding remains unchanged throughout the reduction period [1]. - The total number of shares held by Mr. Shuai Fangwen is 853,574,906 [1].